The treatment paradigm for patients with non-small cell lung cancer (NSCLC) has changed dramatically over the past decades with the emergence of targeted therapies for oncogenic driver alterations and immunotherapy.1, 2, 3, 4 Among Western populations, Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common oncogenic driver alteration in non-squamous NSCLC.5 This evidence concerns the gene KRAS and non-small cell lung carcinoma.